BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

217 related articles for article (PubMed ID: 33150986)

  • 1. Qualitative diagnostic signature for pancreatic ductal adenocarcinoma based on the within-sample relative expression orderings.
    Xia J; Zhang H; Guan Q; Wang S; Li Y; Xie J; Li M; Huang H; Yan H; Chen T
    J Gastroenterol Hepatol; 2021 Jun; 36(6):1714-1720. PubMed ID: 33150986
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A qualitative transcriptional prognostic signature for patients with stage I-II pancreatic ductal adenocarcinoma.
    Huang H; Zou Y; Zhang H; Li X; Li Y; Deng X; Sun H; Guo Z; Ao L
    Transl Res; 2020 May; 219():30-44. PubMed ID: 32119844
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A MicroRNA Signature Identifies Pancreatic Ductal Adenocarcinoma Patients at Risk for Lymph Node Metastases.
    Nishiwada S; Sho M; Banwait JK; Yamamura K; Akahori T; Nakamura K; Baba H; Goel A
    Gastroenterology; 2020 Aug; 159(2):562-574. PubMed ID: 32376411
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Meta-analysis of transcriptome data identifies a novel 5-gene pancreatic adenocarcinoma classifier.
    Bhasin MK; Ndebele K; Bucur O; Yee EU; Otu HH; Plati J; Bullock A; Gu X; Castan E; Zhang P; Najarian R; Muraru MS; Miksad R; Khosravi-Far R; Libermann TA
    Oncotarget; 2016 Apr; 7(17):23263-81. PubMed ID: 26993610
    [TBL] [Abstract][Full Text] [Related]  

  • 5. An Exosome-based Transcriptomic Signature for Noninvasive, Early Detection of Patients With Pancreatic Ductal Adenocarcinoma: A Multicenter Cohort Study.
    Nakamura K; Zhu Z; Roy S; Jun E; Han H; Munoz RM; Nishiwada S; Sharma G; Cridebring D; Zenhausern F; Kim S; Roe DJ; Darabi S; Han IW; Evans DB; Yamada S; Demeure MJ; Becerra C; Celinski SA; Borazanci E; Tsai S; Kodera Y; Park JO; Bolton JS; Wang X; Kim SC; Von Hoff D; Goel A
    Gastroenterology; 2022 Nov; 163(5):1252-1266.e2. PubMed ID: 35850192
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A six-gene signature predicts survival of patients with localized pancreatic ductal adenocarcinoma.
    Stratford JK; Bentrem DJ; Anderson JM; Fan C; Volmar KA; Marron JS; Routh ED; Caskey LS; Samuel JC; Der CJ; Thorne LB; Calvo BF; Kim HJ; Talamonti MS; Iacobuzio-Donahue CA; Hollingsworth MA; Perou CM; Yeh JJ
    PLoS Med; 2010 Jul; 7(7):e1000307. PubMed ID: 20644708
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Gene expression profiling of 1200 pancreatic ductal adenocarcinoma reveals novel subtypes.
    Zhao L; Zhao H; Yan H
    BMC Cancer; 2018 May; 18(1):603. PubMed ID: 29843660
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Early Diagnosis of Pancreatic Ductal Adenocarcinoma by Combining Relative Expression Orderings With Machine-Learning Method.
    Zhang ZM; Wang JS; Zulfiqar H; Lv H; Dao FY; Lin H
    Front Cell Dev Biol; 2020; 8():582864. PubMed ID: 33178697
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Increased CDC20 expression is associated with pancreatic ductal adenocarcinoma differentiation and progression.
    Chang DZ; Ma Y; Ji B; Liu Y; Hwu P; Abbruzzese JL; Logsdon C; Wang H
    J Hematol Oncol; 2012 Apr; 5():15. PubMed ID: 22475564
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A robust qualitative transcriptional signature for the correct pathological diagnosis of gastric cancer.
    Yan H; Li M; Cao L; Chen H; Lai H; Guan Q; Chen H; Zhou W; Zheng B; Guo Z; Zheng C
    J Transl Med; 2019 Feb; 17(1):63. PubMed ID: 30819200
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Global microRNA expression profiling of microdissected tissues identifies miR-135b as a novel biomarker for pancreatic ductal adenocarcinoma.
    Munding JB; Adai AT; Maghnouj A; Urbanik A; Zöllner H; Liffers ST; Chromik AM; Uhl W; Szafranska-Schwarzbach AE; Tannapfel A; Hahn SA
    Int J Cancer; 2012 Jul; 131(2):E86-95. PubMed ID: 21953293
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A qualitative signature for early diagnosis of hepatocellular carcinoma based on relative expression orderings.
    Ao L; Zhang Z; Guan Q; Guo Y; Guo Y; Zhang J; Lv X; Huang H; Zhang H; Wang X; Guo Z
    Liver Int; 2018 Oct; 38(10):1812-1819. PubMed ID: 29682909
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Plasma extracellular vesicle long RNA profiling identifies a diagnostic signature for the detection of pancreatic ductal adenocarcinoma.
    Yu S; Li Y; Liao Z; Wang Z; Wang Z; Li Y; Qian L; Zhao J; Zong H; Kang B; Zou WB; Chen K; He X; Meng Z; Chen Z; Huang S; Wang P
    Gut; 2020 Mar; 69(3):540-550. PubMed ID: 31562239
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Linc00675 is a novel marker of short survival and recurrence in patients with pancreatic ductal adenocarcinoma.
    Li DD; Fu ZQ; Lin Q; Zhou Y; Zhou QB; Li ZH; Tan LP; Chen RF; Liu YM
    World J Gastroenterol; 2015 Aug; 21(31):9348-57. PubMed ID: 26309360
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A gene expression signature for predicting response to neoadjuvant chemoradiotherapy in pancreatic ductal adenocarcinoma.
    Nishiwada S; Sho M; Cui Y; Yamamura K; Akahori T; Nakagawa K; Nagai M; Nakamura K; Takagi T; Ikeda N; Li W; Baba H; Goel A
    Int J Cancer; 2021 Feb; 148(3):769-779. PubMed ID: 32895958
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A microRNA signature in circulating exosomes is superior to exosomal glypican-1 levels for diagnosing pancreatic cancer.
    Lai X; Wang M; McElyea SD; Sherman S; House M; Korc M
    Cancer Lett; 2017 May; 393():86-93. PubMed ID: 28232049
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Metabolic biomarker signature to differentiate pancreatic ductal adenocarcinoma from chronic pancreatitis.
    Mayerle J; Kalthoff H; Reszka R; Kamlage B; Peter E; Schniewind B; González Maldonado S; Pilarsky C; Heidecke CD; Schatz P; Distler M; Scheiber JA; Mahajan UM; Weiss FU; Grützmann R; Lerch MM
    Gut; 2018 Jan; 67(1):128-137. PubMed ID: 28108468
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Plasma extracellular vesicle messenger RNA profiling identifies prognostic EV signature for non-invasive risk stratification for survival prediction of patients with pancreatic ductal adenocarcinoma.
    Han Y; Drobisch P; Krüger A; William D; Grützmann K; Böthig L; Polster H; Seifert L; Seifert AM; Distler M; Pecqueux M; Riediger C; Plodeck V; Nebelung H; Weber GF; Pilarsky C; Kahlert U; Hinz U; Roth S; Hackert T; Weitz J; Wong FC; Kahlert C
    J Hematol Oncol; 2023 Feb; 16(1):7. PubMed ID: 36737824
    [TBL] [Abstract][Full Text] [Related]  

  • 19. MicroRNAs as diagnostic markers for pancreatic ductal adenocarcinoma and its precursor, pancreatic intraepithelial neoplasm.
    Xue Y; Abou Tayoun AN; Abo KM; Pipas JM; Gordon SR; Gardner TB; Barth RJ; Suriawinata AA; Tsongalis GJ
    Cancer Genet; 2013 Jun; 206(6):217-21. PubMed ID: 23933230
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pancreatic cancer survival analysis defines a signature that predicts outcome.
    Raman P; Maddipati R; Lim KH; Tozeren A
    PLoS One; 2018; 13(8):e0201751. PubMed ID: 30092011
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.